Genome & Co
314130
Company Profile
Business description
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.
Contact
Innovalley A-801
Pangyo-ro 253, Bundang-gu
Gyeonggi-do
Seongnam-si13486
KORT: +82 316280150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
98
Stocks News & Analysis
stocks
More gas left in the tank for ASX highflyer
Shares jumped after results and are screening as overvalued.
stocks
Ahead of Earnings, is Apple stock a buy, a sell, or fairly valued?
Following strong holiday sales and a recent AI deal, here’s what we’re watching for in Apple’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,131.15 | 11.90 | -0.15% |
| DAX 40 | 24,933.08 | 32.37 | 0.13% |
| Dow JONES (US) | 49,347.91 | 249.20 | 0.51% |
| FTSE 100 | 10,148.85 | 5.41 | 0.05% |
| HKSE | 26,765.52 | 16.01 | 0.06% |
| NASDAQ | 23,634.46 | 133.22 | 0.57% |
| Nikkei 225 | 52,885.25 | 961.62 | -1.79% |
| NZX 50 Index | 13,460.74 | 12.50 | 0.09% |
| S&P 500 | 6,953.35 | 37.74 | 0.55% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,132.60 | 3.56 | -0.09% |